RxDoctor Payments Data

Anesha Holmes, APRN

Psychiatric/Mental Health · Cayce, SCNPI 1043977887

Payments from drug & device makers

$1,490in general payments, 2019–2025

Across 98 payments — averaging $15.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$378
  • Alkermes, Inc.$261
  • Johnson & Johnson$257
  • Otsuka America Pharmaceutical, Inc.$203
  • Neurocrine Biosciences, Inc.$169
  • E.r. Squibb & Sons, L.L.C.$147
  • plus $74 from 3 others

What the payments were for

  • Food & beverage$1,490100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,490 in reported general payments places this provider in the 65th percentile of 354 psychiatric/mental health providers in South Carolina.

See all psychiatric/mental health providers in South Carolina

Medicare billing

Part B allowed, 2024
$9,312
Medicare patients
64
Services billed
173

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole132$375,481
Invega SustennaPaliperidone Palmitate108$336,486
IngrezzaValbenazine Tosylate14$149,676
AristadaAripiprazole Lauroxil36$114,638
Invega TrinzaPaliperidone Palmitate11$103,109
AustedoDeutetrabenazine12$89,119
Risperdal ConstaRisperidone Microspheres18$26,959
CaplytaLumateperone Tosylate14$24,693
Clozapine41$6,339
Clozapine OdtClozapine11$5,979
Haloperidol Decanoate65$5,071
Fluphenazine Decanoate27$2,861
Aripiprazole78$2,034
Divalproex Sodium ErDivalproex Sodium62$1,902
Quetiapine Fumarate119$1,881

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta$257$466,554137 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$203$375,481132 claims
Neurocrine Biosciences, Inc.Ingrezza$169$149,67614 claims
Alkermes, Inc.Aristada$261$114,63836 claims
Teva Pharmaceuticals USA, Inc.Austedo$378$89,11912 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$20$24,69314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 354 psychiatric/mental health providers in South Carolina.

Other psychiatric/mental health in Cayce

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →